Literature DB >> 30055331

The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease.

Xuhua Tan1, Yihe Chen2, William Foulsham2, Afsaneh Amouzegar2, Takenori Inomata2, Yizhi Liu3, Sunil K Chauhan2, Reza Dana4.   

Abstract

PURPOSE: In this study, we examine the expression of corneal epithelium-derived thrombospondin-1 (TSP-1) and its immunomodulatory functions in a validated murine model of dry eye disease (DED).
METHODS: DED was induced in female C57BL/6 using a controlled environment chamber (CEC) for 14 days. mRNA and protein expression of TSP-1 by corneal epithelial cells was quantified using real-time PCR and flow cytometry. Corneal epithelial cells from either naïve or DED mice were cultured with bone marrow derived dendritic cells (BMDCs) in the presence of IFNγ for 48 h, and BMDC expression of MHC-II and CD86 was determined using flow cytometry. Next, either recombinant TSP-1 or anti-TSP-1 antibody was added to the co-culture, and BMDC expression of above activation markers was evaluated. Finally, either DED mice were topically treated with either recombinant TSP-1 or human serum albumin (HSA), and maturation of corneal DCs, expression of inflammatory cytokines, and DED severity were investigated.
RESULTS: mRNA expression of TSP-1 by the corneal epithelium was upregulated in DED. Corneal epithelial cells derived from mice with DED demonstrated an enhanced capacity in suppressing BMDC expression of MHC-II and CD86 relative to wild type mice, and this effect was abrogated by TSP-1 blockade and potentiated by recombinant TSP-1. Finally, topical application of recombinant TSP-1 significantly suppressed corneal DC maturation and mRNA expression of pro-inflammatory cytokines, and ameliorated disease severity in mice with DED.
CONCLUSIONS: Our study elucidates the function of epithelium-derived TSP-1 in inhibiting DC maturation and shows its translational potential to limit corneal epitheliopathy in DED.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corneal epithelial cells; Dendritic cell; Dry eye disease; Epitheliopathy; Thrombospondin-1

Mesh:

Substances:

Year:  2018        PMID: 30055331      PMCID: PMC6289260          DOI: 10.1016/j.jtos.2018.07.005

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  47 in total

Review 1.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  CD47 engagement inhibits cytokine production and maturation of human dendritic cells.

Authors:  C E Demeure; H Tanaka; V Mateo; M Rubio; G Delespesse; M Sarfati
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 3.  TFOS DEWS II pathophysiology report.

Authors:  Anthony J Bron; Cintia S de Paiva; Sunil K Chauhan; Stefano Bonini; Eric E Gabison; Sandeep Jain; Erich Knop; Maria Markoulli; Yoko Ogawa; Victor Perez; Yuichi Uchino; Norihiko Yokoi; Driss Zoukhri; David A Sullivan
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 4.  Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.

Authors:  Stefano Barabino; Yihe Chen; Sunil Chauhan; Reza Dana
Journal:  Prog Retin Eye Res       Date:  2012-03-08       Impact factor: 21.198

5.  Unique distribution of thrombospondin-1 in human ocular surface epithelium.

Authors:  Eiichi Sekiyama; Takahiro Nakamura; Leanne J Cooper; Satoshi Kawasaki; Junji Hamuro; Nigel J Fullwood; Shigeru Kinoshita
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-04       Impact factor: 4.799

6.  Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis.

Authors:  Yihe Chen; Sunil K Chauhan; Hyun Soo Lee; William Stevenson; Chris S Schaumburg; Zahra Sadrai; Daniel R Saban; Shilpa Kodati; Michael E Stern; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-03       Impact factor: 4.799

7.  Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation.

Authors:  Pedram Hamrah; Ying Liu; Qiang Zhang; M Reza Dana
Journal:  Arch Ophthalmol       Date:  2003-08

8.  Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

Authors:  Francisco Amparo; Mohammad H Dastjerdi; Andre Okanobo; Giulio Ferrari; Leila Smaga; Pedram Hamrah; Ula Jurkunas; Debra A Schaumberg; Reza Dana
Journal:  JAMA Ophthalmol       Date:  2013-06       Impact factor: 7.389

9.  Isolation and characterization of corneal endothelial cells from wild type and thrombospondin-1 deficient mice.

Authors:  Elizabeth A Scheef; Qiong Huang; Shoujian Wang; Christine M Sorenson; Nader Sheibani
Journal:  Mol Vis       Date:  2007-08-27       Impact factor: 2.367

10.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Authors:  S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck
Journal:  Cell       Date:  1998-06-26       Impact factor: 41.582

View more
  10 in total

Review 1.  Thrombospondin-1 in ocular surface health and disease.

Authors:  William Foulsham; Thomas H Dohlman; Sharad K Mittal; Yukako Taketani; Rohan Bir Singh; Sharmila Masli; Reza Dana
Journal:  Ocul Surf       Date:  2019-06-05       Impact factor: 5.033

2.  Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease.

Authors:  Rohan Bir Singh; Tomas Blanco; Sharad K Mittal; Yukako Taketani; Sunil K Chauhan; Yihe Chen; Reza Dana
Journal:  Ocul Surf       Date:  2020-05-06       Impact factor: 5.033

Review 3.  Immune regulation of the ocular surface.

Authors:  Yihe Chen; Shudan Wang; Hamid Alemi; Thomas Dohlman; Reza Dana
Journal:  Exp Eye Res       Date:  2022-03-04       Impact factor: 3.770

4.  Corneal Epithelium-Derived Netrin-1 Alleviates Dry Eye Disease via Regulating Dendritic Cell Activation.

Authors:  Chaoqun Yu; Peng Chen; Jing Xu; Susu Wei; Qilong Cao; Chuanlong Guo; Xianggen Wu; Guohu Di
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

5.  Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response.

Authors:  William Foulsham; Sharad K Mittal; Yukako Taketani; Yihe Chen; Takeshi Nakao; Sunil K Chauhan; Reza Dana
Journal:  Am J Pathol       Date:  2020-04-11       Impact factor: 4.307

6.  Fabrication, Rheological, and Compositional Characterization of Thermoresponsive Hydrogel from Cornea.

Authors:  Ghasem Yazdanpanah; Yizhou Jiang; Behnam Rabiee; Meisam Omidi; Mark I Rosenblatt; Tolou Shokuhfar; Yayue Pan; Alexandra Naba; Ali R Djalilian
Journal:  Tissue Eng Part C Methods       Date:  2021-05       Impact factor: 3.056

Review 7.  Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy.

Authors:  Mostafa Heidari; Farsad Noorizadeh; Kevin Wu; Takenori Inomata; Alireza Mashaghi
Journal:  J Clin Med       Date:  2019-09-11       Impact factor: 4.241

Review 8.  Experimental Pharmacotherapy for Dry Eye Disease: A Review.

Authors:  Monica Baiula; Santi Spampinato
Journal:  J Exp Pharmacol       Date:  2021-03-23

9.  Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.

Authors:  Hurramhon Shokirova; Takenori Inomata; Tsuyoshi Saitoh; Jun Zhu; Kenta Fujio; Yuichi Okumura; Ai Yanagawa; Keiichi Fujimoto; Jaemyoung Sung; Atsuko Eguchi; Maria Miura; Ken Nagino; Kunihiko Hirosawa; Mizu Kuwahara; Yasutsugu Akasaki; Hiroshi Nagase; Akira Murakami
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

10.  Origin and Lineage Plasticity of Endogenous Lacrimal Gland Epithelial Stem/Progenitor Cells.

Authors:  Liana Basova; Geraint J Parfitt; Alex Richardson; Vanessa Delcroix; Takeshi Umazume; Daniel Pelaez; David T Tse; Ivo Kalajzic; Nick Di Girolamo; James V Jester; Helen P Makarenkova
Journal:  iScience       Date:  2020-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.